The effect of hyoscine butylbromide on the swallowing of capsules.
Hyoscine butylbromide (20 mg) given intravenously to 48 patients with normal oesophageal motility significantly reduced oesophageal transit of hard gelatin capsules when swallowed in the erect and supine positions with 15 ml and 60 ml water when compared to an age/sex matched group. Delayed capsule transit and possible failed or slowed drug absorption occurring as a consequence of anti-cholinergic drugs on the oesophagus, constitutes a new drug interaction.
D000328:Adult; D000368:Aged; D002086:Butylscopolammonium Bromide / Q000494:pharmacology*; D002214:Capsules; D003679:Deglutition / Q000187:drug effects*; D004947:Esophagus / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012602:Scopolamine Derivatives / Q000494:pharmacology*; D013997:Time Factors
D002214:Capsules; D012602:Scopolamine Derivatives; D002086:Butylscopolammonium Bromide